有，

來源: fuz 於 2021-10-01 07:37:13 [檔案] [博客] [舊帖] [給我悄悄話] 本文已被閱讀：次 (4505 bytes)

回答: 大廠宣傳就是牛，到現在，媒體上一片正麵期待。安全問題可能很大，沒人敢說？由楓林曉於 2021-10-01 07:01:17

Safety controversy[edit]

In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.^[4] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it.^[5] These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.^[6]

from https://en.wikipedia.org/wiki/Molnupiravir